 This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871 in monotherapy 20 mgkg IV infusion on Day 1 of 3-week cycles. Tumor check-up will be performed every 6-8 weeks. Treatment will be continued until disease progression or unacceptable toxicities according to the patient or the investigator. 